Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
Taysha Gene Therapies, Inc. director and officer Nagendran Sukumar reported an open-market sale of 200,000 shares of common stock on July 10, 2026 at a weighted average price of $6.24 per share. The shares were sold in multiple trades between $5.99 and $6.52 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. Following the transaction, Sukumar holds 936,410 shares of common stock directly.
Taysha Gene Therapies, Inc. shareholder Sukumar Nagendran filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after 07/10/2026 on Nasdaq. The proposed sale has an aggregate market value of $1,298,000. The filer reports prior sales of 200,000 shares during the past three months for $831,300, and discloses stock option grants of 132,063 shares on 01/02/2024 and 67,937 shares on 01/02/2025.
Taysha Gene Therapies is raising about $200.0 million through an underwritten public offering of common stock and pre-funded warrants. The company is selling 32,500,001 common shares at $6.00 each and pre-funded warrants for 833,333 shares at $5.999 per warrant.
Underwriters can buy up to 5,000,000 additional shares within 30 days. Taysha expects net proceeds of about $187.4 million, or $215.6 million if the option is fully exercised. Management believes this cash, combined with existing funds, will finance operations and capital needs into the second half of 2028.
Taysha Gene Therapies is offering 32,500,001 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 833,333 shares at a public offering price of $6.00 per share (pre-funded warrants priced at $5.999). The offering is expected to close on June 26, 2026, and the company estimates net proceeds of approximately $187.4 million before expenses (approximately $215.6 million if underwriters exercise their full 30-day option for 5,000,000 additional shares). The prospectus supplement cites clinical and regulatory progress for TSHA-102 in Rett syndrome (REVEAL and ASPIRE programs) and states the company had 287,276,885 shares outstanding as of March 31, 2026.
Taysha Gene Therapies is offering up to $200,000,000 of common stock and pre-funded warrants in a subject to completion preliminary prospectus supplement dated June 24, 2026. The offering includes pre-funded warrants exercisable at an exercise price of $0.001 per share. The prospectus references 287,276,885 shares outstanding as of March 31, 2026 and reported cash and cash equivalents of $276.6 million as of that date. Net proceeds are intended to support regulatory and commercial manufacturing development, planned BLA activities and the continued clinical and preclinical development of TSHA-102 and other pipeline candidates, including planned Process Performance Qualification activities initiated in April 2026 and expected completion in the fourth quarter of 2026.
Taysha Gene Therapies reported major clinical and regulatory progress for TSHA-102 in Rett syndrome. The company completed dosing of 17 patients in its REVEAL pivotal trial and shared longer-term Phase 1/2 Part A data in 12 females aged 6–21 years.
Across REVEAL Phase 1/2 and pivotal studies (N=29), TSHA-102 was generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities as of the June 2026 cutoff. In Part A, 100% of patients gained or regained at least one developmental milestone, with 310 total functional gains at ≥12 months, including 31 milestones and 279 additional skill gains.
Regulators have aligned that a 6‑month interim analysis from the pivotal trial may support a potential biologics license application, supplemented by Part A data and safety data from the ASPIRE trial in younger patients. Taysha expects topline interim results and FDA feedback on the BLA pathway in the first half of 2027.
Taysha Gene Therapies director John A. Stalfort III reported equity awards in the company’s common stock. He received 21,335 shares through a restricted stock unit award at a price of $0.00 per share. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to his continued service as a director.
He was also granted stock options for 42,671 shares of common stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, he holds 1,176,559 shares of common stock directly and 884,290 shares indirectly through the John A. Stalfort III 2018 Irrevocable Trust.
Taysha Gene Therapies director Phillip B. Donenberg reported equity compensation grants. He received 21,335 shares of Common Stock as a restricted stock unit award at no purchase price. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, if he continues serving as a director.
He was also granted a stock option covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these grants, he directly holds 241,289 shares of Common Stock.
Taysha Gene Therapies director Alison S. Long reported equity compensation awards. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award that will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, contingent on her continued board service.
She was also granted stock options covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 stock options.
Taysha Gene Therapies director Laura Sepp-Lorenzino reported equity awards consisting of restricted stock units and stock options. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award, which will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to her continued service as a director. She was also granted a stock option for 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 options.